Effects of Coenzyme Q10 in PSP and CBD

This study has been completed.

First Received: September 18, 2007 Last Updated: September 19, 2007 History of Changes

Sponsored by:	Lahey Clinic
Information provided by:	Lahey Clinic
ClinicalTrials.gov Identifier:	NCT00532571

Purpose

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Condition	Intervention	Phase
Progressive Supranuclear Palsy Neurological Disorders	Drug: CoQ10	Phase II Phase III

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia

MedlinePlus related topics: Neurologic Diseases Paralysis Progressive Supranuclear Palsy

Drug Information available for: Coenzyme Q10

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Official Title:	Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study

Further study details as provided by Lahey Clinic:

Study Start Date:	January 2004
Estimated Study Completion Date:	September 2005

Eligibility

Ages Eligible for Study:	40 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years
Age > 40
Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.
Patients agreeable to participate in the study.

Exclusion Criteria:

Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
Previous use of coenzyme Q10 within 60 days of the baseline visit.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00532571

Locations

United States, Massachusetts
Lahey Clinic
Burlington, Massachusetts, United States, 01805

Sponsors and Collaborators

Lahey Clinic

Investigators

Principal Investigator:

Diana Apetauerova, MD

Lahey Clinic

More Information

No publications provided

Study ID Numbers:	CoQ10 with PSP/CBD
Study First Received:	September 18, 2007
Last Updated:	September 19, 2007
ClinicalTrials.gov Identifier:	NCT00532571 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Lahey Clinic:

CoQ10
PSP
CBD

Study placed in the following topic categories:

Ganglion Cysts
Eye Diseases
Basal Ganglia Diseases
Central Nervous System Diseases
Trace Elements
Brain Diseases
Neurodegenerative Diseases
Coenzyme Q10
Paralysis
Ocular Motility Disorders

Signs and Symptoms
Movement Disorders
Vitamins
Ubiquinone
Supranuclear Palsy, Progressive
Neurologic Manifestations
Progressive Supranuclear Palsy
Micronutrients
Motor Neuro-ophthalmic Disorders

Additional relevant MeSH terms:

Growth Substances
Eye Diseases
Physiological Effects of Drugs
Nervous System Diseases
Basal Ganglia Diseases
Central Nervous System Diseases
Brain Diseases
Ophthalmoplegia
Neurodegenerative Diseases
Pharmacologic Actions
Coenzyme Q10

Paralysis
Signs and Symptoms
Ocular Motility Disorders
Movement Disorders
Vitamins
Supranuclear Palsy, Progressive
Neurologic Manifestations
Micronutrients
Cranial Nerve Diseases
Tauopathies

ClinicalTrials.gov processed this record on May 07, 2009